Nightingale Health
1.2 EUR -2.76 %4,136 investors are following this company
Nightingale Health operates in medical technology. The company specializes in the development of medical devices. The product portfolio is broad and includes platforms and services in blood tests that are used for disease prevention purposes. In addition to the main business, service and associated ancillary services are also offered. The business is run globally with the largest presence in Europe.
P/E (23e)
-3.95
EV/EBIT (23e)
0.06
P/B (23e)
0.8
Dividend yield-% (23e)
-
Target price
1.30 EUR
Recommendation
Reduce
Updated
24.3.2023
First North Finland
HEALTH
Daily low / high price
1.2 / 1.256
EUR
Market cap
46.91M EUR
Turnover
12.68K EUR
Volume
10K
Risk and recommendation
HighRiskLow
SellRecommendationBuy
Latest research
Analyst
Antti Luiro
Analyst
Latest videos
Financial calendar
Extraordinary general meeting
2023-04-24
Income statement
| 2019 | 2020 | 2021 | 2022 | 2023e | 2024e | 2025e | 2026e | |
|---|---|---|---|---|---|---|---|---|
| Revenue | 2.05 | 1.78 | 2.31 | 2.31 | 4.26 | 5.21 | 8.59 | 16.50 |
| growth-% | 17.10 % | -13.04 % | 29.42 % | 0.35 % | 84.25 % | 22.21 % | 65.00 % | 92.00 % |
| EBITDA | -3.55 | -3.12 | -7.30 | -9.39 | -11.93 | -11.94 | -10.50 | -6.15 |
| EBIT (adj.) | -3.78 | -3.34 | -8.64 | -13.63 | -18.34 | -16.99 | -15.62 | -11.47 |
| EBIT | -3.78 | -3.34 | -9.75 | -13.63 | -18.34 | -16.99 | -15.62 | -11.47 |
| Profit before taxes | -4.02 | -3.73 | -9.72 | -16.19 | -19.72 | -17.31 | -16.29 | -12.54 |
| Net income | -4.02 | -3.73 | -9.73 | -16.09 | -19.72 | -17.31 | -16.29 | -11.91 |
| EPS (adj.) | -0.21 | -0.23 | -0.30 | -0.28 | -0.27 | -0.20 | ||
| growth-% | ||||||||
| Dividend | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Dividend ratio |
Profitability and return on capital
| 2019 | 2020 | 2021 | 2022 | 2023e | 2024e | 2025e | 2026e | |
|---|---|---|---|---|---|---|---|---|
| EBITDA-% | -173.54 % | -174.93 % | -316.75 % | -405.92 % | -279.99 % | -229.20 % | -122.17 % | -37.26 % |
| EBIT-% (adj.) | -184.67 % | -187.65 % | -375.01 % | -589.45 % | -430.38 % | -326.25 % | -181.72 % | -69.52 % |
| EBIT-% | -184.67 % | -187.65 % | -423.17 % | -589.45 % | -430.38 % | -326.25 % | -181.72 % | -69.52 % |
| ROE | -52.10 % | -62.29 % | -15.05 % | -13.73 % | -19.42 % | -20.85 % | -24.60 % | -22.85 % |
| ROI | -24.95 % | -26.12 % | -13.74 % | -11.11 % | -17.36 % | -19.25 % | -20.16 % | -16.42 % |
Valuation
| 2019 | 2020 | 2021 | 2022 | 2023e | 2024e | 2025e | 2026e | |
|---|---|---|---|---|---|---|---|---|
| Share price (EUR) | 3.68 | 1.02 | 1.20 | 1.20 | 1.20 | 1.20 | ||
| Shares | 60.53 | 60.92 | 60.92 | 60.92 | 60.92 | 60.92 | ||
| Market cap | 222.51 | 61.89 | 73.10 | 73.10 | 73.10 | 73.10 | ||
| Enterprise value | 114.58 | -28.85 | -1.02 | 15.89 | 34.03 | 50.64 | ||
| EV/S | - | - | 49.71 | - | - | 3.05 | 3.96 | 3.07 |
| EV/EBITDA | - | - | - | 3.07 | 0.09 | - | - | - |
| EV/EBIT (adj.) | - | - | - | 2.12 | 0.06 | - | - | - |
| EV/EBIT | - | - | - | 2.12 | 0.06 | - | - | - |
| P/E (adj.) | - | - | - | - | - | - | - | - |
| P/E | - | - | - | - | - | - | - | - |
| P/B | - | - | 1.81 | 0.56 | 0.80 | 0.98 | 1.26 | 1.58 |
| P/S | - | - | 96.53 | 26.76 | 17.15 | 14.04 | 8.51 | 4.43 |
| Dividend yield | ||||||||
| Equity ratio | 39.63 % | 23.16 % | 88.52 % | 89.80 % | 87.85 % | 81.24 % | 68.93 % | 59.69 % |
| Gearing ratio | 13.51 % | 87.62 % | -87.41 % | -81.31 % | -80.85 % | -76.93 % | -67.28 % | -48.65 % |
Quarter data
| Q3/22 | Q4/22 | 2022 | Q1/23 | Q2/23 | Q3/23e | Q4/23e | 2023e | Q1/24e | |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | -1.27 | 2.31 | 2.31 | 2.24 | 2.02 | 4.26 | |||
| EBITDA | 4.13 | -9.39 | -9.39 | -5.46 | -6.47 | -11.93 | |||
| EBIT | 5.91 | -13.63 | -13.63 | -8.67 | -9.67 | -18.34 | |||
| Profit before taxes | 5.83 | -16.19 | -16.19 | -8.55 | -11.17 | -19.72 | |||
| Net income | 5.76 | -16.09 | -16.09 | -8.55 | -11.17 | -19.72 |
Showing All content types
